Liver Fibrosis as a Predictive Factor of Response to Pegylated-IFN/ Ribavirin Therapy in Chronic HCV Patients | ||
| The Medical Journal of Cairo University | ||
| Article 100, Volume 89, September, September 2021, Pages 2197-2202 PDF (272.87 K) | ||
| DOI: 10.21608/mjcu.2021.203689 | ||
| Authors | ||
| WAHID DOSS, M.D.; MOHAMED ALI SABER, M.D.; MOHAMMAD EL-SAYED, M.D.; AHMED EL DEEB, M.Sc.; GAMAL ESMAT, M.D.* | ||
| The Department of Endemic Medicine, Gastroenterology & Tropical Hepatology, Faculty of Medicine, Cairo University*, Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute** and National Hepatology & Tropical Medicine Research Institute (NHTMRI)*** | ||
| Abstract | ||
| Abstract Background: The stage of fibrosis is a sensitive predictor of sustained virological response to Pegylated INF/Ribavirin in chronic hepatitis C. Aim of Study: To assess the value of liver fibrosis as a predictor of SVR. Patients and Methods: This study was a retrospective controlled study and was performed on a total number of 240 patients who were treated by PEG-IFN alpha/RBV for 48 weeks and fibrosis stage was done for the all patients. Results: SVR was significant high in patients with F0 and F1 fibrosis stage. Conclusion: The fibrosis stage was a strong pretreatment predictor of response to pegylated interferon and ribavirin therapy in egyptian patients chronically infected with HCV genotype 4. | ||
| Keywords | ||
| HCV-Pegylated Interferon; Liver fibrosis | ||
|
Statistics Article View: 196 PDF Download: 203 |
||
